Dectin-1-mediated suppression of protective anti-mycobacterial immunity

MRC · United Kingdom government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

August 30, 2026
Response Due
Active
Status

Opportunity Overview

Despite over a century of research, tuberculosis remains one of the deadliest bacterial infections in humans, resulting in over one-and-a-half million deaths each year. The important tools for combatting this global problem are the development of new anti-tubercular drugs and a more effective vaccine. Both depend, in large part, on obtaining a better understanding of the interactions between the human 'host' body and this bacterial microbe. We previously found a molecule on the surface of immune cells that senses microbes and activates host immune responses. We call this type of molecule a receptor. Remarkably, our new data now suggest that rather than being beneficial, the actions of this receptor actually increase susceptibility to infection with the bacterium that causes tuberculosis, M. tuberculosis (MTB). Our unpublished data also suggest that these detrimental effects occur, at least in part, through changes in the immune cell's ability to control bacterial growth. This discovery provides vital new insights into the factors underlying susceptibility to tuberculosis. Therefore, we propose to determine how this receptor negatively influences the protective immune responses and the extent to which this impacts human disease.
To do this research, we will use experimental models of MTB infection in mice by comparing normal mice to mice which lack this receptor. We will examine important immune parameters that may be influenced by this receptor at different points during infection, and particularly after the immune system has had time to recognise and respond specifically to M. tuberculosis (known as the adaptive immune response). We will determine which receptor-expressing immune cells (or other cell types) play central roles in these responses. These experiments will allow us to understand how the receptor influences the immune response during infection. We will also use cell lines and tissue culture techniques to explore the role of this receptor in individual...

This is one of 1,831 active United Kingdom Research Development opportunities most of your competitors will never see.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyMRC
CountryUnited Kingdom
CategoryResearch Development
PublishedAugust 31, 2022
Procurement stageActive solicitation
Response dueAugust 30, 2026
StatusOpen — accepting responses
Official sourceView original notice
Last verifiedAugust 12, 2026

Source: UK Research and Innovation (UKRI) — Open Government Licence v3.0.

Related Opportunities in United Kingdom

Rotation year
Title of project: Evaluation of the quantitative accuracy and radiation dosimetry of an advanced pre-clinical multipinhole SPECT/CT theranostic imag
Discerning MCT1s role in chromatin remodelling and metabolomics changes in cancer progression
Leveraging real world data to characterise the long term impact of COVID-19
Bacterial antibiotic resistance: structure, mechanism and inhibition of ABC transporters responsible for drug efflux and cell wall biogenesis.
Characterising the role of TEX12 in centrosome and cilia development
Allogeneic Chondroprogenitor Therapy (Phase II) (ACT2)
Iron and immunity

See every United Kingdom Research Development opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free United Kingdom Research Development intelligence report in your inbox

A personalized report on United Kingdom Research Development opportunities, emailed in 5-10 minutes. One per month, no account needed.